Navigation Links
Isis Pharmaceuticals to Discuss Its Neurodegenerative Franchise in a Conference Call on Thursday, June 17
Date:6/15/2010

isense drugs to treat severe diseases with identified genetic causes.  Isis has initiated several programs to develop drugs to treat severe neurodegenerative disease and funded three of these programs in part through grants.  The most advanced program in Isis' neurodegenerative franchise is its SOD1 drug to treat amyotrophic lateral sclerosis, or ALS, also known as Lou Gehrig's disease.  Isis recently added a drug designed to treat spinal muscular atrophy into its development pipeline and is developing novel treatments for other severe neurodegenerative diseases.

About Isis Pharmaceuticals, Inc.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners.  The Company has successfully commercialized the world's first antisense drug and has 22 drugs in development.  Isis' drug development programs are focused on treating cardiovascular, metabolic, and severe neurodegenerative diseases and cancer.  Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases.  Isis and Alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA therapeutics.  Isis also has made significant innovations beyond human therapeutics resulting in products that other companies, including Abbott, are commercializing.  As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,600 issued patents worldwide.  Additional information about Isis is available at www.isispharm.com.


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... -- Research and Markets has announced the ... 2014" report to their offering. ... professional and in-depth study on the current state of ... provides a basic overview of the industry including definitions, ... market analysis is provided for the international markets including ...
(Date:9/18/2014)... , Sept. 18, 2014  U.S. biotech company ... an exclusive license for technology developed by the ... expression in plants, including for applications in production of ... The technology was developed under the direction of ... Kultevat and former president of the Danforth Plant Science ...
(Date:9/18/2014)... , Sept. 18, 2014 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ... previously announced concurrent but separate underwritten offerings of 10,000,000 ... the public of $2.00 per share, for expected gross ... Series A Convertible Preferred Stock at a price to ... proceeds of $20 million. Each share of Series A ...
(Date:9/18/2014)... (PRWEB) September 18, 2014 OMICS ... the globe to participate in the ‘Open Access ... articles to OMICS Group Pharma Journals ... one of the fastest emerging Sciences, accelerating with ... healthcare services across the globe. The industry is ...
Breaking Biology Technology:Global Human Albumin Industry Report 2014 2Global Human Albumin Industry Report 2014 3Kultevat obtains license of gene switch technology 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 3Pharma and Omics Journals to Address Global Challenges during Open Access Week 2Pharma and Omics Journals to Address Global Challenges during Open Access Week 3
... to Remain as Advisor to Company, FRAZER, Pa., ... its Executive Vice President, General Counsel &,Secretary, John E. ... effective March 31. Mr. Osborn has agreed to remain ... policy matters., "John has been an invaluable member ...
... Inc. (Nasdaq:,EVVV) will release its 2007 fourth quarter and ... market trading hours., The company will host a ... CT (8:30 a.m. ET). ev3 management will review its ... outlook, followed,by a question and answer session., The ...
... Spanish . , ANN ARBOR, Mich.---A new ... to operate a portable GPS locator, a cell phone, ... involving the University of Michigan shows. , A report ... issue of the journal Science. Authors include researchers from ...
Cached Biology Technology:Cephalon General Counsel John E. Osborn to Resign Position 2Cephalon General Counsel John E. Osborn to Resign Position 3ev3 Inc. to Report 2007 Fourth Quarter and Full-Year Financial Results and Host Conference Call on February 22, 2008 2Knee brace generates electricity from walking 2
(Date:9/18/2014)... protective tentacles of host anemones, but new research shows ... across the open ocean. Although the process of long-distance ... the first time that the high level exchange of ... Steve Simpson, Senior Lecturer in Marine Biology and Global ... the Australian Research Council Centre of Excellence for Coral ...
(Date:9/17/2014)... UCLA atmospheric scientists were instrumental in the creation of ... tool to classify the fire threat potential of the ... a spark into an inferno. The index was introduced ... with UCLA and San Diego Gas and Electric. , ... to "extreme" that will be used to help fire ...
(Date:9/17/2014)... and his doctoral student have designed a device based ... from fog and dew., The device could provide water ... the globe., Cheng Luo, professor in the Mechanical & ... the same College of Engineering department, published "Bioinspired Plate-Based ... (American Chemical Society) Applied Materials & Interfaces ...
Breaking Biology News(10 mins):Expedition finds Nemo can travel great distances to connect populations 2Expedition finds Nemo can travel great distances to connect populations 3UCLA scientists play key role in developing new Santa Ana Wildfire Threat Index 2Shorebird's beak inspires UT Arlington research on water collection 2
... of private health insurance and its consequent lack of ... with uterine cancer and may partly explain the mortality ... data presented at the Third AACR Conference on The ... twice as likely to die within four years compared ...
... The convergence in the coming year of three cyclical conditions ... challenges for states that depend on water from the Colorado ... I were concocting a recipe for a perfect drought, this ... and director of UCLA,s Institute of the Environment and Sustainability. ...
... Oct. 1 For the past three decades, saturated fat has ... a result dietary advice persists in recommending reduced consumption of this ... only a very limited impact on CVD risk -- causing many ... A series of research articles published in the October issue of ...
Cached Biology News:Lack of private health insurance impacted cancer survival 2Ocean conditions likely to reduce Colorado River flows during this winter's drought 2Ocean conditions likely to reduce Colorado River flows during this winter's drought 3Ocean conditions likely to reduce Colorado River flows during this winter's drought 4Think saturated fat contributes to heart disease? Think again 2Think saturated fat contributes to heart disease? Think again 3
... Pierce offers maleimide activated carrier proteins ... conjugates. Imject Maleimide Activated Carrier Proteins ... been preactivated with a heterobifunctional cross-linker ... stable, sulfhydryl-reactive carrier protein. Thus ...
...
... A perfect complement to high-speed analytical techniques, the AutoTrace SPE is a ... automates the cartridge conditioning, sample loading and elution steps for large volumes aqueous ... ... ...
Cell Culture Flask, 25 cm, tissue-culture treated polystyrene...
Biology Products: